Your browser is no longer supported. Please, upgrade your browser.
Settings
IMGN ImmunoGen, Inc. daily Stock Chart
IMGN [NASD]
ImmunoGen, Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own0.50% Shs Outstand166.95M Perf Week-9.84%
Market Cap730.67M Forward P/E- EPS next Y-0.77 Insider Trans-12.78% Shs Float145.32M Perf Month-15.63%
Income-89.50M PEG- EPS next Q-0.18 Inst Own80.20% Short Float11.15% Perf Quarter-0.51%
Sales87.00M P/S8.40 EPS this Y41.80% Inst Trans0.46% Short Ratio6.97 Perf Half Y-17.83%
Book/sh-0.02 P/B- EPS next Y-8.60% ROA-38.70% Target Price7.04 Perf Year41.22%
Cash/sh1.33 P/C2.95 EPS next 5Y- ROE177.50% 52W Range1.95 - 7.07 Perf YTD-22.82%
Dividend- P/FCF- EPS past 5Y0.10% ROI124.60% 52W High-44.27% Beta2.39
Dividend %- Quick Ratio- Sales past 5Y-0.80% Gross Margin76.10% 52W Low102.05% ATR0.27
Employees75 Current Ratio3.20 Sales Q/Q54.70% Oper. Margin- RSI (14)38.85 Volatility7.05% 6.10%
OptionableYes Debt/Eq- EPS Q/Q41.10% Profit Margin- Rel Volume0.51 Prev Close3.99
ShortableYes LT Debt/Eq- EarningsJul 31 BMO Payout- Avg Volume2.32M Price3.94
Recom2.20 SMA20-9.45% SMA50-13.02% SMA200-5.53% Volume1,176,124 Change-1.38%
Dec-17-19Reiterated H.C. Wainwright Buy $5 → $9
Aug-13-19Reiterated H.C. Wainwright Buy $4 → $5
May-15-19Downgrade Guggenheim Buy → Neutral
May-06-19Upgrade H.C. Wainwright Neutral → Buy $7
May-06-19Upgrade Cowen Market Perform → Outperform
Mar-19-19Downgrade JP Morgan Neutral → Underweight
Mar-05-19Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-04-19Downgrade SVB Leerink Outperform → Mkt Perform
Mar-04-19Downgrade H.C. Wainwright Buy → Neutral $18 → $3.50
Mar-01-19Downgrade Piper Jaffray Overweight → Neutral $13 → $2.50
Mar-01-19Downgrade Jefferies Buy → Hold
Sep-07-18Initiated Piper Jaffray Overweight
Feb-08-18Resumed RBC Capital Mkts Outperform $12
Jan-31-18Initiated H.C. Wainwright Buy $18
Jul-06-17Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $12
Apr-19-17Upgrade Leerink Partners Mkt Perform → Outperform
Apr-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $18 → $7
Feb-01-16Reiterated RBC Capital Mkts Outperform $19 → $18
Nov-25-15Upgrade Jefferies Hold → Buy
Sep-21-15Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-04-20 11:14AM  
Aug-03-20 04:30PM  
10:53AM  
Jul-31-20 07:03PM  
07:45AM  
07:34AM  
06:30AM  
Jul-29-20 04:30PM  
Jul-27-20 01:08PM  
Jul-24-20 12:30PM  
Jul-22-20 08:00AM  
Jul-20-20 07:00AM  
Jul-16-20 04:01PM  
Jul-14-20 05:31PM  
Jun-23-20 09:42PM  
Jun-22-20 09:01AM  
Jun-03-20 08:00AM  
Jun-02-20 08:00AM  
Jun-01-20 08:00AM  
May-31-20 11:30AM  
May-29-20 08:01AM  
May-20-20 10:04PM  
04:30PM  
03:44PM  
May-19-20 04:08PM  
May-15-20 12:01AM  
May-13-20 05:01PM  
May-06-20 04:30PM  
May-05-20 07:55AM  
May-04-20 04:17PM  
04:05PM  
11:02AM  
09:03AM  
May-01-20 01:31PM  
07:10AM  
06:30AM  
Apr-24-20 12:30PM  
Apr-16-20 04:01PM  
Mar-15-20 11:30AM  
Feb-21-20 10:17AM  
Feb-18-20 08:35AM  
Feb-17-20 09:41AM  
Feb-14-20 05:00PM  
07:45AM  
06:30AM  
Feb-07-20 12:30PM  
Feb-06-20 04:30PM  
Feb-03-20 04:30PM  
09:50AM  
Jan-30-20 04:01PM  
Jan-27-20 04:01PM  
Jan-23-20 07:24AM  
Jan-22-20 08:44PM  
04:01PM  
Jan-03-20 10:46AM  
Dec-31-19 04:01PM  
Dec-24-19 07:12AM  
Dec-19-19 12:50PM  
12:05PM  
09:04AM  
Dec-18-19 08:25AM  
Dec-17-19 04:00PM  
06:30AM  
Dec-14-19 09:13PM  
Dec-09-19 03:01PM  
Dec-01-19 09:30AM  
Nov-26-19 04:30PM  
Nov-18-19 09:34AM  
Nov-10-19 12:50AM  
Nov-07-19 02:51PM  
Nov-06-19 09:01AM  
Nov-05-19 07:29AM  
Nov-04-19 11:54AM  
09:27AM  
Nov-01-19 07:45AM  
06:30AM  
Oct-25-19 10:31AM  
Oct-18-19 04:30PM  
Sep-30-19 09:49AM  
Sep-29-19 06:01AM  
02:31AM  
Sep-26-19 01:18PM  
Sep-17-19 06:30AM  
Sep-01-19 09:30AM  
Aug-07-19 11:20AM  
Aug-06-19 06:51AM  
Aug-05-19 10:18AM  
Aug-02-19 03:00PM  
07:55AM  
06:30AM  
06:00AM  
Jul-26-19 10:30AM  
Jul-18-19 04:30PM  
Jul-12-19 08:58AM  
Jun-28-19 02:23PM  
05:36AM  
Jun-27-19 11:21AM  
06:30AM  
Jun-03-19 06:20PM  
Jun-02-19 09:30AM  
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOSTER DAVID GV.P.-Fin., Prin. Acctg. Off.Apr 02Sale3.435,44818,68721,382Apr 02 03:56 PM
Ryll ThomasSVP, Technical OperationsFeb 24Sale4.9916,79083,78275,624Feb 25 08:38 AM
Berkenblit AnnaSVP & Chief Medical OfficerFeb 24Sale4.9925,803128,75798,089Feb 25 08:37 AM
Enyedy Mark JChief Executive OfficerFeb 24Sale4.9955,222275,558433,776Feb 25 08:38 AM
BARROWS CRAIGExecutive VP, General CounselFeb 24Sale4.9916,49282,295145,275Feb 25 08:36 AM
Wingrove TheresaSVP of Regulatory AffairsFeb 24Sale4.9916,14780,57470,498Feb 25 08:37 AM